Lilly-backed UK biotech raises $72M to advance its antibody approach

Ayisha Sharma

News Reporter

Maxion Therapeutics has secured $72 million in an oversubscribed Series A raise, with Eli Lilly pitching in, to advance its pipeline of antibody-based candidates. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Lilly-backed UK biotech raises $72M to advance its antibody approach

Ayisha Sharma

News Reporter

Sign up to read this article for free.

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

Boston Pharma, building off MASH momentum, mulls an IPO ahead of Phase 3 trial

RFK Jr. convened roundtable around ways to reduce stem cell regulation

Pfizer terminates an early-stage STING agonist trial

UK's plan to hike drugmaker rebates reflects 'broken' system, pharma group says

Recipharm hits record revenue for 2024, eyes GLP-1 contracts for growth

'It’s the law’: Dr. Oz says he would defend Medicare drug price negotiations

Lil­ly-backed UK biotech rais­es $72M to ad­vance its an­ti­body ap­proach

News Reporter

Sign up to read this article for free.

more like this

Gondolabio

Palo Alto, CA, USA

Lilly-backed UK biotech raises $72M to advance its antibody approach